Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 5/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491150 | 1.00 | HTT (0.56) | HTTALDH1A1DHODHCSNK2A1ADORA3 | |
| SCHEMBL20595560 | 0.84 | HTT (0.56) | HTTALDH1A1DHODHCSNK2A1ADORA3 | |
| SCHEMBL5778738 | 0.76 | HTT (0.50) | HTTALDH1A1ADORA3SMN1; SMN2 | |
| SCHEMBL18050722 | 0.73 | AR (0.33) | HTTPARP1 | |
| SCHEMBL8265249 | 0.72 | HTT (0.72) | HTTALDH1A1DHODHCSNK2A1ADORA3 | |
| SCHEMBL9505753 | 0.72 | HTT (1.00) | HTTALDH1A1DHODHADORA3PARP1 | |
| SCHEMBL20309767 | 0.71 | HTT (0.59) | HTTALDH1A1DHODHCSNK2A1ADORA3 | |
| SCHEMBL9386592 | 0.71 | HTT (0.46) | HTTALDH1A1CSNK2A1ADORA3PARP1 | |
| SCHEMBL22224334 | 0.70 | HTT (0.42) | HTTALDH1A1 | |
| SCHEMBL5355856 | 0.69 | HTT (0.68) | HTTALDH1A1DHODHCSNK2A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200223851-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-3472147-B1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-17 | — | — | EP | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190263804-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-29 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3283077-A2 | BROMODOMAIN INHIBITOR | Celgene Quanticel Research, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017216293-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-1472254-A4 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | GLSYNTHESIS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-6926763-B2 | Purine and isosteric antibacterial compounds | GLSYNTHESIS, INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1472254-A2 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | Glsynthesis Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040014773-A1 | Purine and isosteric antibacterial compounds | ACURX PHARMACEUTICALS, LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2003066586-A2 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | GLSYNTHESIS INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263804-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CD, PIK3CB, PIK3CA | HTT 4030/4885ALDH1A1 1422/4885DHODH 607/4885 |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | HTT 1978/4885ALDH1A1 3316/4885DHODH 2497/4885 |
| US-20040014773-A1 | Purine and isosteric antibacterial compounds | MTAP, AMPD3, MPG | HTT 2965/4885ALDH1A1 2828/4885DHODH 494/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | HTT 2084/4885ALDH1A1 3261/4885DHODH 2455/4885 |
| US-10807982-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | HTT 1978/4885ALDH1A1 3316/4885DHODH 2497/4885 |
| US-20200223851-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, CKMT1A; CKMT1B | HTT 93/4885ALDH1A1 1361/4885DHODH 1008/4885 |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | HTT 1978/4885ALDH1A1 3316/4885DHODH 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.